America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How does AOH1996 target specific cancer cell mutations differently than existing cancer therapies?
**Interview with Dr. Linda Malkas on the Development of AOH1996, a Breakthrough Cancer Treatment**
**Editor:** Welcome, Dr. Malkas. Thank you for joining us today to discuss the exciting developments in cancer treatment coming from City of Hope Hospital. Can you start by explaining what AOH1996 is and how it works?
**Dr. Malkas:** Thank you for having me. AOH1996 is an innovative molecule designed for targeted chemotherapy. It specifically targets a variant of the PCNA protein, which is crucial for DNA replication and tumor growth in cancer cells. Think of PCNA as a large airline terminal; cancer cells have a mutated version that allows them to thrive, similar to how airports manage a constant flow of flights. AOH1996 acts like a blizzard that disrupts this flow, selectively killing the cancer cells while sparing healthy ones.
**Editor:** That sounds revolutionary. What types of cancers has this drug been tested on, and what were the results?
**Dr. Malkas:** Over the past two decades, we’ve been able to test AOH1996 on a wide variety of cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. Our research, published in the journal ‘Cell Chemical Biology,’ involved over 70 different cancer cell lines, and the results were promising. The molecule effectively disrupted the normal reproductive cycle of cancer cells, leading to their selective death.
**Editor:** What are the next steps for AOH1996 after these research findings?
**Dr. Malkas:** The next crucial step is to move into clinical trials with human patients. This will allow us to determine the safety and efficacy of the drug in a clinical setting and hopefully bring AOH1996 closer to becoming a viable treatment option for patients.
**Editor:** Given the complexity and the potential impact of this research, how do you view the future of targeted cancer therapies?
**Dr. Malkas:** I believe targeted cancer therapies like AOH1996 represent a significant shift in how we approach cancer treatment. By specifically targeting the unique characteristics of cancer cells, we can potentially minimize side effects and maximize treatment effectiveness. This could lead to improved outcomes for patients and a new standard in cancer care.
**Editor:** Thank you, Dr. Malkas, for such insightful information. We look forward to following the progress of AOH1996 and its potential impact on cancer treatment.
**Dr. Malkas:** Thank you for your interest and support. It’s an exciting time in cancer research!
